Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E91.17 EPS (ttm)1.40 Insider Own0.20% Shs Outstand225.09M Perf Week-0.67%
Market Cap28.71B Forward P/E11.88 EPS next Y10.74 Insider Trans-1.71% Shs Float223.76M Perf Month-3.64%
Income321.50M PEG6.35 EPS next Q2.34 Inst Own98.30% Short Float1.65% Perf Quarter0.00%
Sales4.34B P/S6.61 EPS this Y-95.70% Inst Trans1.69% Short Ratio2.79 Perf Half Y7.53%
Book/sh43.37 P/B2.94 EPS next Y13.42% ROA3.00% Target Price163.28 Perf Year6.85%
Cash/sh7.35 P/C17.35 EPS next 5Y14.37% ROE4.50% 52W Range92.56 - 141.86 Perf YTD31.01%
Dividend- P/FCF76.72 EPS past 5Y-40.60% ROI0.40% 52W High-10.09% Beta1.53
Dividend %- Quick Ratio3.40 Sales past 5Y21.60% Gross Margin91.50% 52W Low37.80% ATR4.12
Employees2656 Current Ratio3.90 Sales Q/Q22.50% Oper. Margin12.00% RSI (14)43.16 Volatility2.46% 2.87%
OptionableYes Debt/Eq0.27 EPS Q/Q102.90% Profit Margin9.60% Rel Volume0.89 Prev Close128.80
ShortableYes LT Debt/Eq0.25 EarningsApr 25 BMO Payout0.00% Avg Volume1.32M Price127.55
Recom1.90 SMA20-3.55% SMA50-4.76% SMA2003.26% Volume1,170,533 Change-0.97%
Apr-10-19Resumed Raymond James Outperform $161
Mar-27-19Reiterated RBC Capital Mkts Outperform $165 → $186
Mar-21-19Reiterated Guggenheim Neutral $135
Feb-22-19Initiated Guggenheim Neutral $135
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
May-21-19 07:46AM  Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay? Zacks
May-20-19 08:45AM  3 Reasons Growth Investors Will Love Alexion (ALXN) Zacks
May-19-19 07:00AM  Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big Motley Fool
May-16-19 09:30AM  ALXN or ALKS: Which Is the Better Value Stock Right Now? Zacks
May-13-19 04:30PM  Alexion to Present at the UBS Global Healthcare Conference Business Wire
04:30PM  Alexion to Present at the RBC Capital Markets Annual Healthcare Conference Business Wire
09:13AM  Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1 Zacks
04:50AM  Alexion Pharmaceuticals, Inc. (ALXN): Sound Shore Says the Pharmaceutical Company is Driving Innovation Insider Monkey
May-09-19 09:00AM  What Makes Alexion (ALXN) a New Buy Stock Zacks
May-07-19 04:57PM  Biotech ETFs in Focus on String of Q1 Earnings Beats Zacks
May-03-19 06:30AM  New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
May-02-19 06:43PM  Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks GuruFocus.com
11:18AM  The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex Zacks
May-01-19 11:52AM  Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks
08:45AM  Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes " Zacks
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
Apr-27-19 08:40AM  Edited Transcript of ALXN earnings conference call or presentation 25-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
Apr-26-19 10:55AM  Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire
Apr-25-19 04:05PM  This Biotech's Newest Drug Could Own The Market In Just 5 Quarters Investor's Business Daily
03:52PM  Alexion Pharmaceuticals Inc (ALXN) Q1 2019 Earnings Call Transcript Motley Fool
02:00PM  Alexion Pharmaceuticals Fires on All Cylinders in Q1 Motley Fool
09:31AM  Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised Zacks
08:52AM  Alexion (ALXN) Tops Q1 Earnings and Revenues Beat Estimates Zacks
08:04AM  Has Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Got Enough Cash? Simply Wall St.
07:56AM  You can find plenty of solid stock bargains in this years worst-performing sector, analysts say MarketWatch
06:49AM  Alexion: 1Q Earnings Snapshot Associated Press
06:30AM  Alexion Reports First Quarter 2019 Results Business Wire
Apr-24-19 04:04PM  Will Biotech ETFs Continue to Rally in Q1 Earnings? Zacks
Apr-23-19 10:10AM  Can Alexion (ALXN) Keep the Earnings Surprise Streak Alive? Zacks
09:46AM  Alexion (ALXN) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-20-19 07:45AM  You can capture a dividend above 5% and still enjoy stock-market growth MarketWatch
Apr-18-19 10:33AM  Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-17-19 01:21PM  Health-care stocks keep getting hammered Wall Street says this is why MarketWatch -8.05%
Apr-16-19 05:54PM  Technician lays out the best bets in biotech CNBC Videos
Apr-12-19 07:06AM  8 Stocks May Jump on Takeovers as Market Nears Peak Investopedia
06:30AM  Alexion to Report First Quarter Results on Thursday, April 25, 2019 Business Wire
Apr-10-19 02:34PM  Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA Zacks
09:15AM  S&P Streak Ends as Stocks Step Back Zacks
Apr-04-19 06:20PM  Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe Reuters
06:16PM  Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe Reuters
12:20PM  Alexion, other drugmakers pay $123M to settle kickback claims American City Business Journals
10:34AM  Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations MarketWatch
10:23AM  Achillion Meets Enrollment Target in Kidney Disease Studies Zacks
Mar-29-19 12:01PM  Is Alexion Pharmaceuticals, Inc. (ALXN) A Good Stock To Buy Right Now? Insider Monkey
Mar-28-19 04:41PM  Achillion Completes Enrollment in Rare Blood Disorder Study Zacks
Mar-27-19 10:55AM  Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks
Mar-24-19 06:33PM  4 Blockbuster Drug Launches to Watch in 2019 Motley Fool
Mar-20-19 04:35PM  IBD 50 Growth Stocks To Watch: After Climbing 403% From A 2009 Breakout, Can This Biotech Surge Again? Investor's Business Daily
07:00AM  Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases Business Wire
06:30AM  Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule Business Wire
Mar-11-19 09:28PM  Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript Motley Fool
02:17PM  If You Had Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Five Years Ago, Youd Be Sitting On A 27% Loss, Today Simply Wall St.
Mar-08-19 09:05AM  Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve Business Wire
Mar-06-19 09:30AM  Why Is Alexion (ALXN) Up 9.7% Since Last Earnings Report? Zacks
08:35AM  Analysis: Positioning to Benefit within Bristol-Myers Squibb, AAR, Central Garden & Pet, Alexion Pharmaceuticals, Tribune Media, and Civitas Solutions Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
04:43AM  Mass. life science leaders say outgoing FDA head was an 'advocate for modernization' American City Business Journals
Mar-05-19 04:30PM  Alexion to Present at the Cowen 39th Annual Health Care Conference Business Wire
Mar-01-19 01:46PM  Final trades: Six Flags, Alexion Pharma, Alphabet, American Express & the financials CNBC Videos
Feb-28-19 02:44PM  These 10 New Drugs Expected In 2019 Are On The Blockbuster Track Investor's Business Daily
08:30AM  Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day Business Wire
Feb-26-19 12:15PM  America's 'inefficient' health care system is driving our fiscal instability: Powell Yahoo Finance
Feb-25-19 03:25PM  5 Clinical-Stage Biotech Stocks to Buy InvestorPlace
Feb-22-19 02:51PM  FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
Feb-21-19 04:30PM  Alexion to Present at the 8th Annual SVB Leerink Global Healthcare Conference Business Wire
09:00AM  Alexion Pharma and Carnival Among Stocks Billionaire Ray Dalio Added in Q4 TheStreet.com
Feb-20-19 04:45PM  IBD 50 Stocks To Watch: Top Biotech Alexion Moves Into Buy Range Investor's Business Daily
Feb-14-19 01:00PM  Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings Zacks
Feb-13-19 01:00PM  Edited Transcript of ALXN earnings conference call or presentation 4-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
09:11AM  The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion Zacks
Feb-12-19 03:18PM  Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp Zacks
09:00AM  Alexion Announces Creation of New Roles on Executive Leadership Team Business Wire
Feb-11-19 08:39AM  Is Alexion (ALXN) a Great Growth Stock? Zacks
Feb-07-19 07:55AM  Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-06-19 09:50AM  Alexion Pharmaceuticals Inc (ALXN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-04-19 04:13PM  Biotech Reports Solid Fourth Quarter, But Slips On Mixed Guidance Investor's Business Daily
04:11PM  Stocks rise amid next batch of corporate earnings Yahoo Finance
02:46PM  Alexion Pharmaceuticals (ALXN) Q4 2018 Earnings Conference Call Transcript Motley Fool
12:45PM  Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks
11:57AM  Stocks making the biggest moves midday: Papa John's, Sysco, Clorox & more CNBC
10:38AM  Economic & Earnings Data Deluge Zacks
10:26AM  Q4 Earnings Soldier on Gamely: GOOGL, CLX & More Zacks
08:54AM  Stocks Open Mixed, Dow Jones Drags Ahead Of Alphabet Earnings Investor's Business Daily
08:39AM  Here's Why Alexion Pharmaceuticals Gained 26.3% in January Motley Fool
08:30AM  Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates Zacks
07:48AM  Stocks making the biggest moves premarket: Papa John's, Spotify, Clorox, Yelp & more CNBC
06:52AM  Alexion: 4Q Earnings Snapshot Associated Press
06:33AM  Evolus Rises Midday as Botox Drama Unfolds Investing.com
06:30AM  Alexion Reports Fourth Quarter and Full Year 2018 Results Business Wire
Feb-01-19 02:06PM  Why Amgen Should Buy Alexion Pharmaceuticals Barrons.com
06:30AM  Alexion to Highlight Rare Disease Portfolio at Investor Day Business Wire
Jan-31-19 07:26PM  Alexion (ALXN) to Report Q4 Earnings: What's in the Cards? Zacks
06:30AM  Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals GlobeNewswire
06:30AM  Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis Business Wire
Jan-29-19 11:10AM  Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks
Jan-28-19 10:01AM  Stock Market Tumbles On Caterpillar Earnings Miss, Nvidia Warning Investor's Business Daily
08:54AM  Stock Market Futures Extend Losses On Big Caterpillar Earnings Miss Investor's Business Daily
06:30AM  Alexion Announces Positive Top-Line Results from Phase 3 Study of ULTOMIRIS (Ravulizumab-cwvz) in Complement Inhibitor-Naïve Patients with atypical Hemolytic Uremic Syndrome (aHUS) Business Wire
Jan-25-19 07:55AM  Analysis: Positioning to Benefit within Cigna, Alexion Pharmaceuticals, Synchrony Financial, Global Medical REIT, Investors Real Estate Trust, and CPI Card Group Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-22-19 04:18PM  Biotech Stock Dips On $700 Million Risk After European Patent Vote Investor's Business Daily
Jan-18-19 09:00AM  Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019 TheStreet.com
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bazarko DanielSVP, Controller, CAOFeb 14Sale126.002,000252,0005,020Feb 19 07:29 PM
HANTSON LUDWIGCEODec 31Sale95.853,244310,937150,696Jan 03 06:07 PM
Franchini Indrani LallEVP, Chief Compliance OfficerNov 28Sale118.132,605307,72929,304Nov 30 06:15 PM
Clancy Paul JEVP, Chief Financial OfficerJul 10Sale131.115,241687,14893,309Jul 12 05:23 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale118.531,466173,76531,909Jun 12 04:52 PM
Goff BrianEVP & Chief Commercial OfficerJun 08Sale118.531,645194,98236,257Jun 12 04:51 PM
LAW ANNE-MARIEEVP and CHROJun 08Sale118.531,862220,70329,450Jun 12 04:51 PM
ORLOFF JOHN JEVP, Research & DevelopmentJun 08Sale118.532,115250,69131,790Jun 12 04:51 PM